CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off - PubMed
3 days ago
- #immunotherapy toxicity
- #immune checkpoint inhibitors
- #CRTAM
- CRTAM inhibition reduces toxicity of immune checkpoint inhibitors without affecting antitumor efficacy.
- CRTAM is identified as a checkpoint specific to immune-related adverse events (irAEs).
- Crtam knockout or T cell lineage-specific ablation reduces irAE induction in preclinical models.
- CRTAM+ T cells infiltrate normal tissues over tumors via CRTAM-cell adhesion molecule 1 interaction, promoting type 3 immunity centered on interleukin 23.
- CRTAM inhibition maintains a 'hot' tumor microenvironment for efficacy while reducing toxicity.
- The CRTAM-type 3 immune axis in blood samples can monitor irAEs in ICB-treated cohorts.